Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents.
about
New targets for therapy in breast cancer: small molecule tyrosine kinase inhibitorsProteomic identification of putative biomarkers of radiotherapy resistance: a possible role for the 26S proteasome?Microarray analysis of DNA damage repair gene expression profiles in cervical cancer cells radioresistant to 252Cf neutron and X-rays.Endostar down-regulates HIF-1 and VEGF expression and enhances the radioresponse to human lung adenocarcinoma cancer cells.Targeting Phosphatidylinositide3-Kinase/Akt pathway by BKM120 for radiosensitization in hepatocellular carcinomaBax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma.Targeting angiogenesis with integrative cancer therapies.Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approachesA gene expression model of intrinsic tumor radiosensitivity: prediction of response and prognosis after chemoradiation.Radiosensitizers in cervical cancer. Cisplatin and beyond.Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.Inositol hexaphosphate suppresses growth and induces apoptosis in HT-29 colorectal cancer cells in culture: PI3K/Akt pathway as a potential target.Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy.Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1.Radiogenic therapy: novel approaches for enhancing tumor radiosensitivity.New concepts for phase I trials: evaluating new drugs combined with radiation therapy.A molecular assay of tumor radiosensitivity: a roadmap towards biology-based personalized radiation therapy.Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinomaAugmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3-kinase inhibition in the human cervical cancer cell-line.Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform.Targeting inflammatory pathways for tumor radiosensitization.Towards novel radiosensitizing agents: the role of cytosolic PLA2α in combined modality cancer therapy.Radiotherapeutic strategies in the management of hepatocellular carcinoma.Genes and molecular pathways related to radioresistance of oral squamous cell carcinoma cells.Effect of all-trans retinoic acid on the growth of two nasopharyngeal cancer cell lines and its treatment potential in combination with cisplatin.Solute carrier protein family may involve in radiation-induced radioresistance of non-small cell lung cancer.SiRNA-mediated IGF-1R inhibition sensitizes human colon cancer SW480 cells to radiation.The biological effectiveness of targeted radionuclide therapy based on a whole-body pharmacokinetic model.Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.Peptide Mediated In Vivo Tumor Targeting of Nanoparticles through Optimization in Single and Multilayer In Vitro Cell Models.
P2860
Q24806486-DDD05620-0B7D-4650-9BF7-6B4024398206Q33514439-205CDB01-30D4-492C-9CC8-8ED3CC688F2BQ33534471-38C69B05-980F-4E56-B4F6-638833EB20F3Q33897862-1FE20D35-CC19-4142-BEC3-8C810FF41013Q33977001-2175BA4C-4AB5-4665-ACFC-66AEE9C2BBC9Q34361458-7DDA1AF3-4A56-4BBB-8418-F8E4960B3C05Q34495463-83F18A37-0F58-4F8F-8347-B9C9E5A54A15Q34515465-89AB4C01-BECE-4540-8809-9C526CA2FB64Q34572724-E92BC526-58BB-4D39-B474-544A018DEA23Q34684307-43D53862-878D-4771-8DE6-B48A332047CBQ35025403-CD9D4870-B950-424E-8496-1D973A103331Q35405450-32DA003C-9FEE-4A6E-AB43-81777FD1E630Q35576159-5D37D4F1-E2C8-4011-8C0C-6A3EBBA944C0Q35584153-7CE54308-60CC-47E1-A6ED-B70C309ABECAQ35840331-CECC5AF9-729E-4D54-A39F-45EE56507651Q36200146-05EF808F-922C-43D5-A81E-04B0FE374A83Q36304022-AECB65DF-005B-4CAE-9A81-62D57E86C03EQ36344539-FB3375AB-46CD-4F6D-9971-CD3CB98D65BDQ37002044-1DD524DC-98A2-4CE3-85B9-25E36AD32778Q37197236-A2F8F589-CBCD-4C5B-8D06-804E7F30CB76Q37341722-DC45DF05-290C-44EF-80F4-E3F62BD58E13Q37388535-6796E186-DDF1-411F-8DC5-5098FB269511Q37769804-B7F8569B-E873-4C9C-B002-3D911AF249E6Q37885347-94C39B26-CC78-4F77-AA0E-1D77FCEFA007Q37972813-19DA287D-9B32-4DD2-8F34-7ABF5C250059Q38516742-8291FE27-1385-4553-AE10-29559C70EF0BQ39335891-7A0F8C78-3C09-43DF-BE97-EB05D0E959EDQ39475768-7AB36418-4514-49B3-9B10-F4569455029FQ39764987-448D4022-7FE2-44B8-B677-5694560EB831Q42010261-F87A48AB-22F1-4DAC-AA23-CB881921C6DFQ45880240-75F91818-CE7D-4C87-A006-24EDD0332528Q52646682-4DD80BAF-5245-4DD5-ADC8-4CA985BAC49F
P2860
Combined-modality treatment of solid tumors using radiotherapy and molecular targeted agents.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Combined-modality treatment of ...... and molecular targeted agents.
@ast
Combined-modality treatment of ...... and molecular targeted agents.
@en
type
label
Combined-modality treatment of ...... and molecular targeted agents.
@ast
Combined-modality treatment of ...... and molecular targeted agents.
@en
prefLabel
Combined-modality treatment of ...... and molecular targeted agents.
@ast
Combined-modality treatment of ...... and molecular targeted agents.
@en
P2093
P356
P1476
Combined-modality treatment of ...... and molecular targeted agents.
@en
P2093
Brigette B Y Ma
Lillian L Siu
Robert G Bristow
P304
P356
10.1200/JCO.2003.10.044
P407
P577
2003-07-01T00:00:00Z